Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.
about
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future PerspectivesThe comprehensive neuro-oncology data repository (CONDR): a research infrastructure to develop and validate imaging biomarkersMR Imaging Biomarkers in Oncology Clinical TrialsGenomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.Multimodal MR imaging model to predict tumor infiltration in patients with gliomas.Magnetic resonance perfusion imaging in neuro-oncology.Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging.Imaging biomarkers in primary brain tumours.The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Clinical neuroimaging using arterial spin-labeled perfusion magnetic resonance imaging.A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas.Advanced MRI in the management of adult gliomas.The role of advanced MR imaging in understanding brain tumour pathology.Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumorsMRI for identification of progression in brain tumors: from morphology to function.Imaging of central nervous system tumors in children: advances and limitations.Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.Clinical impact of integrated physiologic brain tumor imaging.Prognostic value of blood flow measurements using arterial spin labeling in gliomasMR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas.Comparative analysis of arterial spin labeling and dynamic susceptibility contrast perfusion imaging for quantitative perfusion measurements of brain tumorsDynamic Contrast-Enhanced Perfusion MRI and Diffusion-Weighted Imaging in Grading of GliomasClinical applications of dynamic susceptibility contrast perfusion-weighted MR imaging in brain tumours.Voxel-based clustered imaging by multiparameter diffusion tensor images for glioma grading.Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.Correlation between cerebral blood volume measurements by perfusion-weighted magnetic resonance imaging and two-year progression-free survival in gliomas.Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor gradeSurvival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).Gliomas: application of cumulative histogram analysis of normalized cerebral blood volume on 3 T MRI to tumor grading.Cerebral blood volume analysis in glioblastomas using dynamic susceptibility contrast-enhanced perfusion MRI: a comparison of manual and semiautomatic segmentation methods.Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons.Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standardHypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumoursDynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialDevelopment of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment.
P2860
Q26774810-51A2230A-1032-4AC1-BE28-5717373E4C14Q28608269-F581C007-D2B8-4BD5-8270-711B7967DEEBQ30364608-A79CD8AE-C033-40E7-B116-5190BF4BDDCBQ30414111-7B6C6589-E13A-4AF0-B705-B747143E0FA4Q30457230-A6F2F484-6E43-42DB-B8BE-6977634B0703Q30479156-25E92460-A1CD-4670-A52C-BD2ED904B020Q30653828-FF7C5B64-774F-49A3-B092-4F8027DBD394Q30818733-A1581AA3-63D8-4690-A499-8117161A0A62Q30880129-FA272E2C-C372-48B6-9B43-B8E4A4728A7CQ31016200-373D9E65-475A-4C64-861F-6B8EB613F32FQ31117148-5727759B-389E-43D9-B3D0-437C4E15FF80Q31130548-27D6D2B6-0736-4A95-89DC-3DD6D5CEBBDEQ31139548-73B3BBE8-F1A9-4351-AF40-2CB332590685Q33309683-1CCBC342-3167-4FEA-B462-4546A18F5A38Q33368027-4BF0E43C-F633-4EC2-8D1B-DFF8588EC5F0Q33377547-6327FBBB-6550-4DF1-95EF-7885F30D45EFQ33379510-09B629B3-A669-4239-8240-B9725D527DCBQ33562673-6648689E-8FF2-4B0F-8E17-7BC308987F42Q33616589-D651AC46-8285-439A-9D73-292ACA0AC8BDQ33631461-EEF003AF-1591-4472-B641-86B98C386232Q33727772-76A0BD98-9252-4EC0-93AD-09F6C3F9CB9DQ33812703-76C7C6D1-0838-4E7E-BD98-3298633F80A3Q33898480-5ADA452D-91FF-4F84-B46E-5D5B61DDCD9DQ33925725-73FAFA73-52A0-48CC-BF13-CCDB89352021Q34011150-89FD1BA3-FB3F-45E8-8D66-A59DC095752AQ34092867-D8CF9EA1-653F-48A4-98A7-E8ABA2D5F476Q34203930-6F72CC35-D935-462E-BA13-7D176EC08021Q34369456-B3B0FA59-3058-4FE5-89DE-3C81EEE3E558Q34369508-4EA4E2A2-7DDD-4CE7-8AD1-BAF5B2C55970Q34389144-E9C4837D-0EFF-4621-A9D6-34CF1EAC224EQ34722851-150EE5F3-FFB8-4D34-AD74-001C09B9F1D1Q34737443-F9781355-8F0D-4574-BA69-555C2A7B6B8EQ34946279-CC8D13CA-B421-4119-9800-CE34CCACB039Q35068619-9E54D528-6CC2-4B8C-8B53-7CF824D4EEE7Q35070122-5BE32BD0-0C0C-44DD-838A-3234F1958B07Q35090720-061307AE-022A-4BDB-A977-C8D4383ED907Q35093286-18EC1C3A-C3CF-40EA-BC7D-36FBD2EE1F30Q35811181-BAF5A771-24AC-4F63-9FDF-CDCF8C3EE6B4Q35815291-7BE26BD7-6908-4DF6-B943-3348A9CFC16DQ36275542-F501803A-41F6-4660-A4BB-62B3BFDC962C
P2860
Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Low-grade gliomas: dynamic sus ...... of patient clinical response.
@en
Low-grade gliomas: dynamic sus ...... of patient clinical response.
@nl
type
label
Low-grade gliomas: dynamic sus ...... of patient clinical response.
@en
Low-grade gliomas: dynamic sus ...... of patient clinical response.
@nl
prefLabel
Low-grade gliomas: dynamic sus ...... of patient clinical response.
@en
Low-grade gliomas: dynamic sus ...... of patient clinical response.
@nl
P2093
P1433
P1476
Low-grade gliomas: dynamic sus ...... of patient clinical response.
@en
P2093
David Zagzag
Edmond A Knopp
Edwin Wang
James S Babb
Matilde Inglese
P304
P356
10.1148/RADIOL.2382042180
P407
P50
P577
2006-01-05T00:00:00Z